The article, "Cannabinoid-1 Receptor Antagonist, Rimonabant, for Management of Obesity and Related Risks” by Gadde and Allison that appeared in the August 29, 2006 issue (Circulation. 2006;114:974-984) contained the following errors: On pages 976-977, while discussing the results of RIO-Europe, it was stated that the proportions of patients losing at least 5% of their weight in the rimonabant 20-mg, rimonabant 5-mg, and placebo groups were 67%, 44%, and 31%, respectively. The corrected statement should read that the proportions of patients losing at least 5% of their weight in the rimonabant 20-mg, rimonabant 5-mg, and placebo groups were 51%, 33%, and 19%, respectively. Table 1 (page 979) incorrectly noted that the mean placebo-subtracted 1-year weight loss for sibutramine in the study by Apfelbaum et al was 4.7 kg. The correct mean placebo-subtracted (simple subtraction, not based on the estimates obtained from the analysis of variance model) 1-year weight loss for sibutramine in the study by Apfelbaum et al was 5.7 kg. This correction has been made to the current online version of the article, available at http://circ.ahajournals.org/cgi/content/full/114/9/974. The authors regret the error.